Key clinical point: Guselkumab demonstrated promising efficacy and was well tolerated in a real-world population of patients with psoriatic arthritis (PsA) and psoriasis.
Major finding: Before starting guselkumab, 48% of patients had moderate/high disease activity in PsA (DAPSA). In this subgroup, the mean DAPSA score reduced from 29 to 20, 16, and 14 at weeks 12, 24, and 52, respectively (P < .0001). Only 2.2% of patients reported mild adverse events.
Study details: Findings are from a multicenter, retrospective, observational study including 90 patients with PsA and concomitant psoriasis who started treatment with guselkumab.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Rocamora V et al. Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis Group. Dermatol Ther. 2022 (Sep 29). Doi: 10.1111/dth.15865